In an 82‑year‑old woman with severe anemia (hemoglobin 7.7 g/dL), what is the significance of a white‑blood‑cell count of 13.4 ×10⁹/L, platelet count of 351 ×10⁹/L, and macrocytic mean corpuscular volume of 103.2 fL, and how should she be managed?

Macrocytic Anemia with Mild Leukocytosis and Thrombocytosis in an 82-Year-Old Woman

This 82-year-old woman with severe macrocytic anemia (Hb 7.7 g/dL, MCV 103.2 fL), mild leukocytosis (WBC 13.4), and elevated platelets (351) most likely has vitamin B12 or folate deficiency, though myelodysplastic syndrome (MDS) must be excluded given her age and the severity of anemia.

Significance of Laboratory Findings

The MCV of 103.2 fL indicates macrocytic anemia (>100 fL), which most commonly reflects megaloblastic processes—primarily vitamin B12 or folate deficiency 1. However, the combination of findings warrants careful consideration:

• Severe anemia (Hb 7.7 g/dL) at this level is symptomatic and requires urgent evaluation
• Mild leukocytosis (WBC 13.4) is nonspecific but can occur with B12 deficiency or suggest underlying inflammation/infection
• Elevated platelets (351) may indicate reactive thrombocytosis from chronic anemia, inflammation, or could be part of a primary bone marrow disorder

Critical distinction: While macrocytosis strongly suggests nutritional deficiency, MDS and certain drugs (hydroxyurea, azathioprine) also cause macrocytosis 1. In elderly patients, MDS becomes an important differential, particularly when anemia is severe and refractory to vitamin replacement 2.

Immediate Diagnostic Workup

The minimum essential workup must include 3:

1. Reticulocyte count (corrected for anemia degree)

   • Low/normal reticulocytes → decreased RBC production (deficiency or bone marrow failure)
   • High reticulocytes → hemolysis (though less likely with macrocytosis)

2. Vitamin B12 and folate levels

   • B12 <150 pmol/L indicates deficiency 4
   • Folate <10 nmol/L indicates deficiency 4

3. Peripheral blood smear review

   • Look for hypersegmented neutrophils (megaloblastic changes)
   • Assess for dysplastic features suggesting MDS
   • Rule out schistocytes (hemolysis) 1

4. Additional markers 3:

   • Serum ferritin and transferrin saturation (exclude combined iron deficiency)
   • LDH, indirect bilirubin, haptoglobin (assess for hemolysis component)
   • CRP (assess inflammation)
   • Methylmalonic acid if B12 borderline (>271 nmol/L confirms deficiency) 4

If B12 deficiency confirmed, test for anti-intrinsic factor antibodies to diagnose pernicious anemia, especially given potential autoimmune clustering in elderly patients 5.

Management Algorithm

Step 1: Assess Hemodynamic Stability and Symptoms

Transfusion decision should NOT be based solely on Hb threshold 1. Evaluate:

• Symptomatic anemia (dyspnea, chest pain, dizziness, severe fatigue) → transfuse immediately
• Asymptomatic with significant comorbidities (cardiovascular, pulmonary, cerebrovascular disease) → strongly consider transfusion 1
• Asymptomatic without comorbidities → may observe with close monitoring

At Hb 7.7 g/dL in an 82-year-old, transfusion is likely indicated given age-related cardiovascular risk and inability to compensate for severe anemia 1, 6. Transfuse 1-2 units PRBCs (each unit raises Hb ~1 g/dL) to relieve symptoms and achieve Hb 8-9 g/dL 1.

Step 2: Initiate Vitamin Replacement

If vitamin B12 deficiency confirmed (or highly suspected pending results):

• Start intramuscular cyanocobalamin immediately (1000 mcg daily for 1 week, then weekly, then monthly maintenance) 5
• Add oral folic acid 1 mg daily if folate deficiency present or suspected 7
• Monitor CBC weekly during initial treatment to assess response 3

Expected response: Reticulocyte count rises within 3-7 days; Hb should increase ≥2 g/dL within 4 weeks 3. Platelet and WBC abnormalities typically normalize with treatment 5.

Step 3: Rule Out MDS if No Response

If no hematologic improvement after 2-4 weeks of adequate vitamin replacement, or if peripheral smear shows dysplastic features, bone marrow biopsy is mandatory to exclude MDS 1, 2. This is particularly critical in patients >80 years with severe macrocytic anemia.

Common Pitfalls to Avoid

1. Do not assume macrocytosis always means B12/folate deficiency: Up to 35% of macrocytic anemia in some series is due to primary bone marrow disorders 2. Age >80 years increases MDS probability.

2. Do not rely on MCV alone: Studies show MCV has poor sensitivity (17-77%) for detecting B12 deficiency depending on population 8. Combined deficiencies (iron + B12) can normalize MCV, masking both 3, 9.

3. Do not delay vitamin replacement waiting for test results if clinical suspicion is high and patient is symptomatic—treatment is safe and diagnostic response confirms diagnosis 5, 2.

4. Do not overlook hemolysis: Severe B12 deficiency can present with hemolytic features (elevated LDH, indirect bilirubin, low haptoglobin) mimicking autoimmune hemolytic anemia 5, 10. Check these markers.

5. Monitor for neurologic complications: B12 deficiency causes irreversible neurologic damage if untreated. Assess for paresthesias, ataxia, cognitive changes 5.

Summary of Recommended Actions

Immediate (within 24 hours):

• Assess symptoms and cardiovascular status
• Transfuse 1-2 units PRBCs if symptomatic or high-risk comorbidities
• Order: reticulocyte count, B12, folate, peripheral smear, LDH, ferritin, CRP

Within 48-72 hours:

• Start IM B12 1000 mcg daily if deficiency confirmed/suspected
• Add folic acid 1 mg daily if indicated

Week 1-4:

• Monitor CBC weekly
• Expect reticulocytosis by day 3-7, Hb rise ≥2 g/dL by week 4

If no response by week 4:

• Refer to hematology
• Proceed with bone marrow biopsy to exclude MDS

1, 3, 1, 3, 5, 2